Navigation Links
Peramivir Phase 2 Data for the Treatment of Outpatient Influenza to be Presented at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
Date:10/20/2008

ressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein include that our belief that many subjects in the Phase 2 clinical trials of peramivir did not receive adequate dosing by intramuscular injection may not be correct, that HHS and the Food & Drug Administration (FDA) may not agree with our analysis, that HHS may further condition, reduce or eliminate future funding of the peramivir program, that ongoing peramivir clinical trials may not be successful, that the peramivir program may not be successful, that the pivotal trial with forodesine HCl in cutaneous T-cell lymphoma (CTCL) may not meet its endpoint, that development and commercialization of forodesine HCl in CTCL may not be successful, that we or our licensees may not be able to enroll the required number of subjects in planned clinical trials of our product candidates and that such clinical trials may not be successfully completed, that BioCryst or its licensees may not commence as expected additional human clinical trials with our product candidates, that our product candidates may not receive required regulatory clearances from the FDA, that ongoing and future preclinical and clinical development may not have positive results, that we or our licensees may not be able to continue future development of our current and future development programs, that our development programs may never result in future product, license or royalty payments being received by BioCryst, that BioCryst may not be able to retain its current pharmaceutical and biotechnology partners for further development of its product candidates or it may not reach favorable agreements with potential pharmaceutical and biotec
'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
2. Isolagen to Host Investor Conference Call to Present an Analysis of the Data from Phase III Wrinkle Studies
3. Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
6. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
7. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
8. BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
11. AEterna Zentaris Completes Patient Recruitment for Second Efficacy Trial of its Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Albany, New York (PRWEB) September 23, 2014 ... advocates from around the globe will convene ... 11th International Conference, to be held October ... latest in evidence-based research and practice in ... includes physicians, scientists, researchers, nurses, psychologists, nutritionists, ...
(Date:9/23/2014)... CAMBRIDGE, England , September 23, 2014 /PRNewswire/ ... UK launched with funding from Imperial Innovations, Cambridge Innovation ... Inivata, a clinical cancer genomics company focused ... (ctDNA) analysis to improve cancer testing and treatment, ... funding round led by Imperial Innovations and including ...
(Date:9/22/2014)... September 22, 2014 Pearl's Premium Ultra ... in drought tolerant grass seed this week with the ... The announcement coincides with the fact that it is ... as many believe. , As of the date ... favorable reviews by industry experts and the media including: ...
(Date:9/22/2014)... 22, 2014 Research and ... of the "Global Biotechnology Reagents Market 2014-2018" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents are chemical ... system to detect and examine another substance to ... in laboratories to prepare, collect, and examine specimens ...
Breaking Biology Technology:International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 2International Medical Experts to Discuss Latest Integrative Oncology Research and Its Translation to Personalized Clinical Care at 11th International Conference of SIO 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3
... , , ... ("China Pharma") (NYSE Amex: CPHI ), which develops,manufactures, and ... present at the Brean Murray, Carret & Co. 2009 China,Growth ... Broadway,hotel in New York. Management is scheduled to present ...
... , CRACKS AMAZON.COM BEST SELLER LIST IN SCIENCE ... top ten best selling science books , SEATTLE, Nov. 17 ... new book about the controversial theory of intelligent design made Amazon.com,s ... as the world marks 150 years since Charles Darwin published his ...
... , KVISTGARD, ... today that BARDA (Biomedical Advanced Research and,Development Authority) has ... of a freeze-dried version of its IMVAMUNE(R) smallpox vaccine,with ... The contract provides funds to ...
Cached Biology Technology:China Pharma Holdings, Inc. to Present at Brean Murray China Growth Conference 2Intelligent Design Book Delivers Blow to Darwin 2US Government Awards Contract to Bavarian Nordic for the Development of Freeze-Dried IMVAMUNE(R) Smallpox Vaccine 2US Government Awards Contract to Bavarian Nordic for the Development of Freeze-Dried IMVAMUNE(R) Smallpox Vaccine 3
(Date:9/23/2014)... NJ. September 23, 2014. Kessler Foundation scientists have ... foot drop stimulator during a task-specific movement for ... finding indicates that applying the foot drop stimulator ... common complication of stroke. "EMG of the tibialis ... a foot drop stimulator," was published online ahead ...
(Date:9/23/2014)... identified a gene mutation that causes aplastic anemia, ... marrow fails to produce normal amounts of blood ... had blood disorders, the researchers discovered a defect ... with crucial roles in normal cell function. , ... molecular-based treatments that bypass the gene defect and ...
(Date:9/23/2014)... for your mental as your physical health, new research ... Warwick,s Medical School using data from the Health Survey ... focused on mental wellbeing and found that high and ... fruit and vegetable consumption. , 33.5% of respondents with ... fruit and vegetables a day, compared with only 6.8% ...
Breaking Biology News(10 mins):Gene mutation discovered in blood disorder 2Eating five a day may keep the blues away 2
... is allowing scientists to better understand the movement of cells ... microenvironment. In a recent article published in Disease Models ... colleagues used optimized methods of laser microscopy to track the ... cancer. As a tumor grows, it triggers ...
... Activity in Identity ... Management and Biometrics, FALLS CHURCH, Va., Sept. ... relocating the CSC Identity Labs headquarters from Camp,Hill, Pa., to Fairmont, ... alignment with the federal government,s presence in the,I-79 High Technology Corridor, ...
... FL (September 16, 2008)- A team of scientists headed by neuroscientist ... grant by the National Institute of Health (NIH), to develop a ... injury. Dr. Chiba, a professor at the University of Miami,s Department ... groundbreaking process to enhance synapse formation or nerve regeneration., ...
Cached Biology News:CSC Identity Labs Headquarters Relocates to West Virginia 2CSC Identity Labs Headquarters Relocates to West Virginia 3NIH EUREKA grant awarded to University of Miami scientist 2
... AmpliTaq DNA Polymerase is the most thoroughly ... a testimony to its overall utility and ... it ideal for PCR applications. , ... results. ,, AmpliTaq DNA Polymerase is ...
... DNA Polymerase is a versatile and easy-to ... PCR applications. GCpro Taq DNA Polymerase is ... E. coli, containing the DNA polymerase I ... a highly processive 5'-3' DNA polymerase activity. ...
Taq DNA Polymerase (cloned), 250 units. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Polymerases....
APO(a) EIA Sample Size: 25 l...
Biology Products: